HOSPITAL PROFESSIONAL NEWS IRELAND
HPN November 2021 Issue 90 HOSPITALPROFESSIONALNEWS.IE
Ireland’s Dedicated Hospital Professional Publication
IN THIS ISSUE:
CONFRONT R/R CLL
NEWS: Historic Mental Health Deficit Cleared Page 4 REPORT: Is Hospital Pharmacy Facing the Perfect Storm? Page 8 FEATURE: Future of Digital Diabetes Page 19
VENCLYXTO® in combination with rituximab is NOW AVAILABLE for the treatment of adult patients with CLL who have received at least one prior therapy1
INDICATIONS1: VENCLYXTO® in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) (see section 5.1) †. VENCLYXTO® in combination with rituximab is indicated for the treatment of adult patients with CLL who have received at least one prior therapy*. VENCLYXTO® monotherapy is indicated for the treatment of CLL in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B cell receptor pathway inhibitor or in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B cell receptor pathway inhibitor*. VENCLYXTO® in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy †. Full Summary of Product Characteristics is available at www.medicines.ie. ▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance; Website: www.hpra.ie. Suspected adverse events should also be reported to AbbVie Limited on 01-4287900. LEGAL CATEGORY: POM (S1A). MARKETING AUTHORISATION NUMBERS/PRESENTATIONS: 10mg film-coated tablet, 14 tablets, EU/1/16/1138/002; 50mg filmcoated tablet, 7 tablets, EU/1/16/1138/004; 100mg film-coated tablet, 7 tablets, EU/1/16/1138/005;100mg film-coated tablet, 14 tablets, EU/1/16/1138/006; 100mg film-coated tablet, 112 tablets, EU/1/16/1138/007. MARKETING AUTHORISATION HOLDER: AbbVie Deutschland GmbH & Co. KG, Knollstrasse, 67061 Ludwigshafen, Germany. Further information is available from AbbVie Limited, 14 Riverwalk, Citywest Business Campus, Dublin 24, Ireland. † Indications are not reimbursed. * Indications are reimbursed. R/R, Relapsed/Refractory. References: 1. VENCLYXTO® Summary of Product Characteristics, available at www.medicines.ie. IE-VNCLY-210025 Date of Preparation: July 2021
This Publication is for Healthcare Professionals Only
PERSPECTIVES: The Role of Hospitals in Protecting the Environment Page 28 CPD: Management and Treatment of Lung Cancer Page 39 MEN’S HEALTH SPECIAL FOCUS: Testicular Tumours Page 46 MEN’S HEALTH SPECIAL FOCUS: Obesity Page 61